

# CY 2016 OPPS/ASC PROPOSED RULE

## Addendum O: New CY 2016 Category I and III CPT Codes Effective January 1, 2016

CPT codes and descriptions only are copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.

**NOTE 1:** The proposed payment rates for these codes can be found in the OPPS Addendum B, ASC Addendum AA, and ASC Addendum BB to this proposed rule, which is available via the Internet on the CMS Web site.

**NOTE 2:** Comment Indicator (CI) "NP" = New code for the next calendar year or existing code with substantial revision to its code descriptor in the next calendar year as compared to current calendar year, proposed payment indicator; comments will be accepted on the proposed payment indicator for the new code.

**NOTE 3:** Comments will NOT be accepted for new Category I CPT lab codes that are not assigned to "NP" comment indicator. Comments to these codes must be submitted at the Clinical Lab Fee Schedule (CLFS) Public Meeting, which is scheduled for July 16, 2015.

CY 2016 OPPS/ASC Proposed Rule 5-Digit CMS Placeholder Code	Long Descriptor	Comment Indicator (CI)
1003I	Placement of soft tissue localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous, including imaging guidance; first lesion	NP
1003J	Placement of soft tissue localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous, including imaging guidance; each additional lesion (List separately in addition to code for primary procedure)	NP
3160A	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with endobronchial ultrasound (EBUS) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]), one or two mediastinal and/or hilar lymph node stations or structures	NP
3160B	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with endobronchial ultrasound (EBUS) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]), 3 or more mediastinal and/or hilar lymph node stations or structures	NP
3160C	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transendoscopic endobronchial ultrasound (EBUS) during bronchoscopic diagnostic or therapeutic intervention(s) for peripheral lesion(s) (List separately in addition to code for primary procedure[s])	NP
3347A	Transcatheter pulmonary valve implantation, percutaneous approach, including pre-stenting of the valve delivery site, when performed	NP
3725A	Intravascular ultrasound (noncoronary vessel) during diagnostic evaluation and/or therapeutic intervention, including radiological supervision and interpretation; initial non-coronary vessel (List separately in addition to code for primary procedure)	NP
3725B	Intravascular ultrasound (noncoronary vessel) during diagnostic evaluation and/or therapeutic intervention, including radiological supervision and interpretation; each additional noncoronary vessel (List separately in addition to code for primary procedure)	NP
3940A	Mediastinoscopy; includes biopsy(ies) of mediastinal mass (eg, lymphoma), when performed	NP
3940B	Mediastinoscopy; with lymph node biopsy(ies) (eg, lung cancer staging)	NP
4321A	Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed	NP
4753A	Injection procedure for cholangiography, percutaneous, complete diagnostic procedure including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation; existing access	NP
4753B	Injection procedure for cholangiography, percutaneous, complete diagnostic procedure including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation; new access (eg, percutaneous transhepatic cholangiogram)	NP
4753C	Placement of biliary drainage catheter, percutaneous, including diagnostic cholangiography when performed, imaging guidance (eg, ultrasound and/or fluoroscopy), and all associated radiological supervision and interpretation; external	NP
4753D	Placement of biliary drainage catheter, percutaneous, including diagnostic cholangiography when performed, imaging guidance (eg, ultrasound and/or fluoroscopy), and all associated radiological supervision and interpretation; internal-external	NP

# CY 2016 OPPS/ASC PROPOSED RULE

## Addendum O: New CY 2016 Category I and III CPT Codes Effective January 1, 2016

CPT codes and descriptions only are copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.

**NOTE 1: The proposed payment rates for these codes can be found in the OPPS Addendum B, ASC Addendum AA, and ASC Addendum BB to this proposed rule, which is available via the Internet on the CMS Web site.**

**NOTE 2: Comment Indicator (CI) "NP" = New code for the next calendar year or existing code with substantial revision to its code descriptor in the next calendar year as compared to current calendar year, proposed payment indicator; comments will be accepted on the proposed payment indicator for the new code.**

**NOTE 3: Comments will NOT be accepted for new Category I CPT lab codes that are not assigned to "NP" comment indicator. Comments to these codes must be submitted at the Clinical Lab Fee Schedule (CLFS) Public Meeting, which is scheduled for July 16, 2015.**

CY 2016 OPPS/ASC Proposed Rule 5-Digit CMS Placeholder Code	Long Descriptor	Comment Indicator (CI)
4753E	Conversion of external biliary drainage catheter to internal-external biliary drainage catheter, percutaneous, including diagnostic cholangiography when performed, imaging guidance (eg, fluoroscopy), and all associated radiological supervision and interpretation	NP
4753F	Exchange of biliary drainage catheter (eg, external, internal-external, or conversion of internal/-external to external only), percutaneous, including diagnostic cholangiography when performed, imaging guidance (eg, fluoroscopy), and all associated radiological supervision and interpretation	NP
4753G	Removal of biliary drainage catheter, percutaneous, requiring fluoroscopic guidance (eg, with concurrent indwelling biliary stents), including diagnostic cholangiography when performed, imaging guidance (eg, fluoroscopy), and all associated radiological supervision and interpretation	NP
4753H	Placement of stent(s) into a bile duct, percutaneous, including diagnostic cholangiography, imaging guidance (eg, fluoroscopy and/or ultrasound), balloon dilation, catheter exchange or removal when performed, and all associated radiological supervision and interpretation, each stent; existing access	NP
4753I	Placement of stent(s) into a bile duct, percutaneous, including diagnostic cholangiography, imaging guidance (eg, fluoroscopy and/or ultrasound), balloon dilation, catheter exchange or removal when performed, and all associated radiological supervision and interpretation, each stent; new access, without placement of separate biliary drainage catheter	NP
4754J	Placement of stent(s) into a bile duct, percutaneous, including diagnostic cholangiography, imaging guidance (eg, fluoroscopy and/or ultrasound), balloon dilation, catheter exchange or removal when performed, and all associated radiological supervision and interpretation, each stent; new access, with placement of separate biliary drainage catheter (eg, external or internal-external)	NP
4754K	Placement of access through the biliary tree and into small bowel to assist with an endoscopic biliary procedure (eg, rendezvous procedure), percutaneous, including diagnostic cholangiography when performed, imaging guidance (eg, ultrasound and/or fluoroscopy), and all associated radiological supervision and interpretation, new access	NP
4754L	Balloon dilation of biliary duct(s) or of ampulla (sphincteroplasty), percutaneous, including imaging guidance (eg, fluoroscopy), and all associated radiological supervision and interpretation, each duct (List separately in addition to code for primary procedure)	NP
4754M	Endoluminal biopsy(ies) of biliary tree, percutaneous, any method(s) (eg, brush, forceps, and/or needle), including imaging guidance (eg, fluoroscopy), and all associated radiological supervision and interpretation, single or multiple (List separately in addition to code for primary procedure)	NP
4754N	Removal of calculi/debris from biliary duct(s) and/or gallbladder, percutaneous, including destruction of calculi by any method (eg, mechanical, electrohydraulic, lithotripsy) when performed, imaging guidance (eg, fluoroscopy), and all associated radiological supervision and interpretation (List separately in addition to code for primary procedure)	NP
4918A	Sclerotherapy of a fluid collection (eg, lymphocele, cyst, or seroma), percutaneous, including contrast injection(s), sclerosant injection(s), diagnostic study, imaging guidance (eg, ultrasound, fluoroscopy) and radiological supervision and interpretation when performed	NP

# CY 2016 OPPS/ASC PROPOSED RULE

## Addendum O: New CY 2016 Category I and III CPT Codes Effective January 1, 2016

CPT codes and descriptions only are copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.

**NOTE 1: The proposed payment rates for these codes can be found in the OPPS Addendum B, ASC Addendum AA, and ASC Addendum BB to this proposed rule, which is available via the Internet on the CMS Web site.**

**NOTE 2: Comment Indicator (CI) "NP" = New code for the next calendar year or existing code with substantial revision to its code descriptor in the next calendar year as compared to current calendar year, proposed payment indicator; comments will be accepted on the proposed payment indicator for the new code.**

**NOTE 3: Comments will NOT be accepted for new Category I CPT lab codes that are not assigned to "NP" comment indicator. Comments to these codes must be submitted at the Clinical Lab Fee Schedule (CLFS) Public Meeting, which is scheduled for July 16, 2015.**

CY 2016 OPPS/ASC Proposed Rule 5-Digit CMS Placeholder Code	Long Descriptor	Comment Indicator (CI)
5039A	Injection procedure for antegrade nephrostogram and/or ureterogram, complete diagnostic procedure including imaging guidance (eg, ultrasound and fluoroscopy) and all associated radiological supervision and interpretation; new access	NP
5039B	Injection procedure for antegrade nephrostogram and/or ureterogram, complete diagnostic procedure including imaging guidance (eg, ultrasound and fluoroscopy) and all associated radiological supervision and interpretation; existing access	NP
5039C	Placement of nephrostomy catheter, percutaneous, including diagnostic nephrostogram and/or ureterogram when performed, imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation	NP
5039D	Placement of nephroureteral catheter, percutaneous, including diagnostic nephrostogram and/or ureterogram when performed, imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation, new access	NP
5039M	Convert nephrostomy catheter to nephroureteral catheter, percutaneous, including diagnostic nephrostogram and/or ureterogram when performed, imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation, via pre-existing nephrostomy tract	NP
5039E	Exchange nephrostomy catheter, percutaneous, including diagnostic nephrostogram and/or ureterogram when performed, imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation	NP
5059F	Endoluminal biopsy of ureter and/or renal pelvis, non-endoscopic, including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation (List separately in addition to code for primary procedure)	NP
5069G	Placement of ureteral stent, percutaneous, including diagnostic nephrostogram and/or ureterogram when performed, imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation; pre-existing nephrostomy tract	NP
5069H	Placement of ureteral stent, percutaneous, including diagnostic nephrostogram and/or ureterogram when performed, imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation; new access, without separate nephrostomy catheter	NP
5069I	Placement of ureteral stent, percutaneous, including diagnostic nephrostogram and/or ureterogram when performed, imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation; new access, with separate nephrostomy catheter	NP
5070K	Ureteral embolization or occlusion, including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation (List separately in addition to code for primary procedure)	NP
5070L	Balloon dilation, ureteral stricture, including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation (List separately in addition to code for primary procedure)	NP
5443A	Repair of traumatic corporeal tear(s)	NP
5443B	Replantation, penis, complete amputation including urethral repair	NP

# CY 2016 OPPS/ASC PROPOSED RULE

## Addendum O: New CY 2016 Category I and III CPT Codes Effective January 1, 2016

CPT codes and descriptions only are copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.

**NOTE 1:** The proposed payment rates for these codes can be found in the OPPS Addendum B, ASC Addendum AA, and ASC Addendum BB to this proposed rule, which is available via the Internet on the CMS Web site.

**NOTE 2:** Comment Indicator (CI) "NP" = New code for the next calendar year or existing code with substantial revision to its code descriptor in the next calendar year as compared to current calendar year, proposed payment indicator; comments will be accepted on the proposed payment indicator for the new code.

**NOTE 3:** Comments will **NOT** be accepted for new Category I CPT lab codes that are not assigned to "NP" comment indicator. Comments to these codes must be submitted at the Clinical Lab Fee Schedule (CLFS) Public Meeting, which is scheduled for July 16, 2015.

CY 2016 OPPS/ASC Proposed Rule 5-Digit CMS Placeholder Code	Long Descriptor	Comment Indicator (CI)
6164A	Percutaneous arterial transluminal mechanical thrombectomy and/or infusion for thrombolysis, intracranial, any method, including diagnostic angiography, fluoroscopic guidance, catheter placement, and intraprocedural pharmacological thrombolytic injection(s)	NP
6164B	Endovascular intracranial prolonged administration of pharmacologic agent(s) other than for thrombolysis, arterial, including catheter placement, diagnostic angiography, and imaging guidance; initial vascular territory	NP
6164C	Endovascular intracranial prolonged administration of pharmacologic agent(s) other than for thrombolysis, arterial, including catheter placement, diagnostic angiography, and imaging guidance; each additional vascular territory (List separately in addition to code for primary procedure)	NP
6446A	Paravertebral block (PVB) (paraspinous block), thoracic; single injection site (includes imaging guidance, when performed)	NP
6446B	Paravertebral block (PVB) (paraspinous block), thoracic; second and any additional injection site(s), (includes imaging guidance, when performed) (List separately in addition to code for primary procedure)	NP
6446C	Paravertebral block (PVB) (paraspinous block), thoracic; continuous infusion by catheter (includes imaging guidance, when performed)	NP
657XG	Implantation of intrastromal corneal ring segments	NP
692XX	Removal impacted cerumen using irrigation/lavage, unilateral	NP
7208A	Radiologic examination, spine, entire thoracic and lumbar, including skull, cervical and sacral spine if performed (eg, scoliosis evaluation); one view	NP
7208B	Radiologic examination, spine, entire thoracic and lumbar, including skull, cervical and sacral spine if performed (eg, scoliosis evaluation); 2 or 3 views	NP
7208C	Radiologic examination, spine, entire thoracic and lumbar, including skull, cervical and sacral spine if performed (eg, scoliosis evaluation); 4 or 5 views	NP
7208D	Radiologic examination, spine, entire thoracic and lumbar, including skull, cervical and sacral spine if performed (eg, scoliosis evaluation); minimum of 6 views	NP
7350A	Radiologic examination, hip, unilateral, with pelvis when performed; 1 view	NP
7350B	Radiologic examination, hip, unilateral, with pelvis when performed; 2-3 views	NP
7350C	Radiologic examination, hip, unilateral, with pelvis when performed; minimum of 4 views	NP

# CY 2016 OPPS/ASC PROPOSED RULE

## Addendum O: New CY 2016 Category I and III CPT Codes Effective January 1, 2016

CPT codes and descriptions only are copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.

**NOTE 1:** The proposed payment rates for these codes can be found in the OPPS Addendum B, ASC Addendum AA, and ASC Addendum BB to this proposed rule, which is available via the Internet on the CMS Web site.

**NOTE 2:** Comment Indicator (CI) "NP" = New code for the next calendar year or existing code with substantial revision to its code descriptor in the next calendar year as compared to current calendar year, proposed payment indicator; comments will be accepted on the proposed payment indicator for the new code.

**NOTE 3:** Comments will **NOT** be accepted for new Category I CPT lab codes that are not assigned to "NP" comment indicator. Comments to these codes must be submitted at the Clinical Lab Fee Schedule (CLFS) Public Meeting, which is scheduled for July 16, 2015.

CY 2016 OPPS/ASC Proposed Rule 5-Digit CMS Placeholder Code	Long Descriptor	Comment Indicator (CI)
7352A	Radiologic examination, hips, bilateral, with pelvis when performed; 2 views	NP
7352B	Radiologic examination, hips, bilateral, with pelvis when performed; 3-4 views	NP
7352C	Radiologic examination, hips, bilateral, with pelvis when performed; minimum of 5 views	NP
7355A	Radiologic examination, femur; 1 view	NP
7355B	Radiologic examination, femur; minimum 2 views	NP
747XA	Magnetic resonance (eg, proton) imaging, fetal, including placental and maternal pelvic imaging when performed; single or first gestation	NP
747XB	Magnetic resonance (eg, proton) imaging, fetal, including placental and maternal pelvic imaging when performed; each additional gestation (List separately in addition to code for primary procedure)	NP
7778A	Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed; lesion diameter up to 2.0 cm or 1 channel	NP
7778B	Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple lesions	NP
7778C	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 1 channel	NP
7778D	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 2-12 channels	NP
7778E	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; over 12 channels	NP
782XA	Gastric emptying imaging study (eg, solid, liquid, or both); with small bowel transit, up to 24 hours	NP
782XB	Gastric emptying imaging study (eg, solid, liquid, or both); with small bowel and colon transit, multiple days	NP
800XA	Obstetric panel This panel must include the following: Blood count, complete (CBC), and automated differential WBC count (85025 or 85027 and 85004) OR Blood count, complete (CBC), automated (85027) and appropriate manual differential WBC count (85007 or 85009) Hepatitis B surface antigen (HBsAg) (87340) HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result (87389) Antibody, rubella (86762) Syphilis test, non-treponemal antibody; qualitative (eg, VDRL, RPR, ART) (86592) Antibody screen, RBC, each serum technique (86850) Blood typing, ABO (86900) AND Blood typing, Rh (D) (86901) (When syphilis screening is performed using a treponemal antibody approach [86780], do not use 800XX1. Use the individual codes for the tests performed in the Obstetric panel)	
812XX	BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis and full duplication/deletion analysis	

# CY 2016 OPPS/ASC PROPOSED RULE

## Addendum O: New CY 2016 Category I and III CPT Codes Effective January 1, 2016

CPT codes and descriptions only are copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.

**NOTE 1:** The proposed payment rates for these codes can be found in the OPPS Addendum B, ASC Addendum AA, and ASC Addendum BB to this proposed rule, which is available via the Internet on the CMS Web site.

**NOTE 2:** Comment Indicator (CI) "NP" = New code for the next calendar year or existing code with substantial revision to its code descriptor in the next calendar year as compared to current calendar year, proposed payment indicator; comments will be accepted on the proposed payment indicator for the new code.

**NOTE 3:** Comments will **NOT** be accepted for new Category I CPT lab codes that are not assigned to "NP" comment indicator. Comments to these codes must be submitted at the Clinical Lab Fee Schedule (CLFS) Public Meeting, which is scheduled for July 16, 2015.

CY 2016 OPPS/ASC Proposed Rule 5-Digit CMS Placeholder Code	Long Descriptor	Comment Indicator (CI)
812XH	ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) (eg, acquired imatinib tyrosine kinase inhibitor resistance), gene analysis, variants in the kinase domain	
812XG	CEBPA (CCAAT/enhancer binding protein [C/EBP], alpha) (eg, acute myeloid leukemia), gene analysis, full gene sequence	
812XT	CALR (calreticulin) (eg, myeloproliferative disorders), gene analysis, common variants in exon 9	
812X0	KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) (eg, gastrointestinal stromal tumor [GIST], acute myeloid leukemia, melanoma), gene analysis, targeted sequence analysis (eg, exons 8, 11, 13, 17, 18)	
812XC	KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) (eg, mastocytosis), gene analysis, D816 variant(s)	
8127F	KRAS (Kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis; additional variant(s) (eg, codon 61, codon 146)	
812XI	NRAS (neuroblastoma RAS viral [v-ras] oncogene homolog) (eg, colorectal carcinoma), gene analysis, variants in exon 2 (eg, codons 12 and 13) and exon 3 (eg, codon 61)	
813XX	PDGFRA (platelet-derived growth factor receptor, alpha polypeptide) (eg, gastrointestinal stromal tumor [GIST]), gene analysis, targeted sequence analysis (eg, exons 12, 18)	
814XB	Ashkenazi Jewish associated disorders (eg, Bloom syndrome, Canavan disease, cystic fibrosis, familial dysautonomia, Fanconi anemia group C, Gaucher disease, Tay-Sachs disease), genomic sequence analysis panel, must include sequencing of at least 9 genes, including ASPA, BLM, CFTR, FANCC, GBA, HEXA, IKBKAP, MCOLN1, and SMPD1	
814XL	Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); genomic sequence analysis panel, must include sequencing of at least 14 genes, including ATM, BRCA1, BRCA2, BRIP1, CDH1, MLH1, MSH2, MSH6, NBN, PALB2, PTEN, RAD51C, STK11, and TP53	
814XM	Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); duplication/deletion analysis panel, must include analyses for BRCA1, BRCA2, MLH1, MSH2, and STK11	
814XP	Hereditary retinal disorders (eg, retinitis pigmentosa, Leber congenital amaurosis, cone-rod dystrophy), genomic sequence analysis panel, must include sequencing of at least 15 genes, including ABCA4, CNGA1, CRB1, EYS, PDE6A, PDE6B, PRPF31, PRPH2, RDH12, RHO, RP1, RP2, RPE65, RPGR, and USH2A	
814XE	Hereditary neuroendocrine tumor disorders (eg, medullary thyroid carcinoma, parathyroid carcinoma, malignant pheochromocytoma or paraganglioma); genomic sequence analysis panel, must include sequencing of at least 6 genes, including MAX, SDHB, SDHC, SDHD, TMEM127, and VHL	
814XF	Hereditary neuroendocrine tumor disorders (eg, medullary thyroid carcinoma, parathyroid carcinoma, malignant pheochromocytoma or paraganglioma); duplication/deletion analysis panel, must include analyses for SDHB, SDHC, SDHD, and VHL	

# CY 2016 OPPS/ASC PROPOSED RULE

## Addendum O: New CY 2016 Category I and III CPT Codes Effective January 1, 2016

CPT codes and descriptions only are copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.

**NOTE 1: The proposed payment rates for these codes can be found in the OPPS Addendum B, ASC Addendum AA, and ASC Addendum BB to this proposed rule, which is available via the Internet on the CMS Web site.**

**NOTE 2: Comment Indicator (CI) "NP" = New code for the next calendar year or existing code with substantial revision to its code descriptor in the next calendar year as compared to current calendar year, proposed payment indicator; comments will be accepted on the proposed payment indicator for the new code.**

**NOTE 3: Comments will NOT be accepted for new Category I CPT lab codes that are not assigned to "NP" comment indicator. Comments to these codes must be submitted at the Clinical Lab Fee Schedule (CLFS) Public Meeting, which is scheduled for July 16, 2015.**

CY 2016 OPPS/ASC Proposed Rule 5-Digit CMS Placeholder Code	Long Descriptor	Comment Indicator (CI)
814XD	Noonan spectrum disorders (eg, Noonan syndrome, cardio-facio-cutaneous syndrome, Costello syndrome, LEOPARD syndrome, Noonan-like syndrome), genomic sequence analysis panel, must include sequencing of at least 12 genes, including BRAF, CBL, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, PTPN11, RAF1, RIT1, SHOC2, and SOS1	
815XM	Autoimmune (rheumatoid arthritis), analysis of 12 biomarkers using immunoassays, utilizing serum, prognostic algorithm reported as a disease activity score	
815XO	Coronary artery disease, mRNA, gene expression profiling by real-time RT-PCR of 23 genes, utilizing whole peripheral blood, algorithm reported as a risk score	
815XY	Oncology (colon), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a recurrence score	
815XB	Oncology (colorectal) screening, quantitative real-time target and signal amplification of 10 DNA markers (KRAS mutations, promoter methylation of NDRG4 and BMP3) and fecal hemoglobin, utilizing stool, algorithm reported as a positive or negative result	
815XI	Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by DAPI stain and morphology, predictive algorithm reported as a drug response score; first single drug or drug combination	
815XP	Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by DAPI stain and morphology, predictive algorithm reported as a drug response score; each additional single drug or drug combination (List separately in addition to code for primary procedure)	
815XL	Oncology (lung), mass spectrometric 8-protein signature, including amyloid A, utilizing serum, prognostic and predictive algorithm reported as good versus poor overall survival	
815XN	Oncology (tumor of unknown origin), mRNA, gene expression profiling by real-time RT-PCR of 92 genes (87 content and 5 housekeeping) to classify tumor into main cancer type and subtype, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a probability of a predicted main cancer type and subtype	
815XS	Oncology (thyroid), gene expression analysis of 142 genes, utilizing fine needle aspirate, algorithm reported as a categorical result (eg, benign or suspicious)	
815XQ	Cardiology (heart transplant), mRNA, gene expression profiling by real-time quantitative PCR of 20 genes (11 content and 9 housekeeping), utilizing subfraction of peripheral blood, algorithm reported as a rejection risk score	
8835X	Immunofluorescence, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure)	NP
883XI	Reflectance confocal microscopic images of skin, interpretation and report, referred after primary interpretation, each lesion	NP
907XA	Cholera vaccine, live, adult dosage, 1 dose schedule, for oral use	NP
9254A	Caloric vestibular test with recording, bilateral; bithermal (ie, one warm and one cool irrigation in each ear for a total of four irrigations)	NP

# CY 2016 OPPS/ASC PROPOSED RULE

## Addendum O: New CY 2016 Category I and III CPT Codes Effective January 1, 2016

CPT codes and descriptions only are copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.

**NOTE 1:** The proposed payment rates for these codes can be found in the OPPS Addendum B, ASC Addendum AA, and ASC Addendum BB to this proposed rule, which is available via the Internet on the CMS Web site.

**NOTE 2:** Comment Indicator (CI) "NP" = New code for the next calendar year or existing code with substantial revision to its code descriptor in the next calendar year as compared to current calendar year, proposed payment indicator; comments will be accepted on the proposed payment indicator for the new code.

**NOTE 3:** Comments will **NOT** be accepted for new Category I CPT lab codes that are not assigned to "NP" comment indicator. Comments to these codes must be submitted at the Clinical Lab Fee Schedule (CLFS) Public Meeting, which is scheduled for July 16, 2015.

CY 2016 OPPS/ASC Proposed Rule 5-Digit CMS Placeholder Code	Long Descriptor	Comment Indicator (CI)
9254B	Caloric vestibular test with recording, bilateral; monothermal (ie, one irrigation in each ear for a total of two irrigations)	NP
9300A	Arterial pressure waveform analysis for assessment of central arterial pressures, includes obtaining waveform(s), digitization and application of nonlinear mathematical transformations to determine central arterial pressures and augmentation index, with interpretation and report, upper extremity artery, non-invasive	NP
969XA	Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; image acquisition and interpretation and report, first lesion	NP
969XB	Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; image acquisition only	NP
969XC	Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; interpretation and report only	NP
969XD	Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; image acquisition and interpretation and report, each additional lesion (List separately in addition to code for primary procedure)	NP
969XE	Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; image acquisition only, each additional lesion (List separately in addition to code for primary procedure)	NP
969XF	Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; interpretation and report only, each additional lesion (List separately in addition to code for primary procedure)	NP
9917X	Instrument-based ocular screening (eg, photoscreening, automated-refraction), bilateral; with on-site analysis	NP
9935A	Prolonged clinical staff service (the service beyond the typical service time) during an evaluation and management service in the office or outpatient setting, direct patient contact with physician supervision; first hour (List separately in addition to code for outpatient Evaluation and Management service)	NP
9935B	Prolonged clinical staff service (the service beyond the typical service time) during an evaluation and management service in the office or outpatient setting, direct patient contact with physician supervision; each additional 30 minutes (List separately in addition to code for prolonged service)	NP
01XXT	High dose rate electronic brachytherapy, skin surface application, per fraction, includes basic dosimetry, when performed	NP
02XXT	High dose rate electronic brachytherapy, interstitial or intracavitary treatment, per fraction, includes basic dosimetry, when performed	NP
039FT	Intra-operative use of kinetic balance sensor for implant stability during knee replacement arthroplasty (List separately in addition to code for primary procedure)	NP
039GT	Endoscopic retrograde cholangiopancreatography (ERCP), with optical endomicroscopy (List separately in addition to code for primary procedure)	NP
03XXA	Magnetic resonance image guided high intensity focused ultrasound (MRgFUS), stereotactic ablation lesion, intracranial for movement disorder including stereotactic navigation and frame placement when performed	NP

# CY 2016 OPPS/ASC PROPOSED RULE

## Addendum O: New CY 2016 Category I and III CPT Codes Effective January 1, 2016

CPT codes and descriptions only are copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.

**NOTE 1:** The proposed payment rates for these codes can be found in the OPPS Addendum B, ASC Addendum AA, and ASC Addendum BB to this proposed rule, which is available via the Internet on the CMS Web site.

**NOTE 2:** Comment Indicator (CI) "NP" = New code for the next calendar year or existing code with substantial revision to its code descriptor in the next calendar year as compared to current calendar year, proposed payment indicator; comments will be accepted on the proposed payment indicator for the new code.

**NOTE 3:** Comments will **NOT** be accepted for new Category I CPT lab codes that are not assigned to "NP" comment indicator. Comments to these codes must be submitted at the Clinical Lab Fee Schedule (CLFS) Public Meeting, which is scheduled for July 16, 2015.

CY 2016 OPPS/ASC Proposed Rule 5-Digit CMS Placeholder Code	Long Descriptor	Comment Indicator (CI)
039XI	Myocardial strain imaging (quantitative assessment of myocardial mechanics using image-based analysis of local myocardial dynamics)	NP
039XA	Multi-spectral digital skin lesion analysis of clinically atypical cutaneous pigmented lesions for detection of melanomas and high risk melanocytic atypia; one to five lesions	NP
039XB	Multi-spectral digital skin lesion analysis of clinically atypical cutaneous pigmented lesions for detection of melanomas and high risk melanocytic atypia; six or more lesions	NP
03XXB	Collagen cross-linking of cornea (including removal of the corneal epithelium and intraoperative pachymetry when performed)	NP
0XXXX	Preventive behavior change, intensive program of prevention of diabetes using a standardized diabetes prevention program curriculum, provided to individuals in a group setting, minimum 60 minutes, per day	NP
04XXD	Transcervical uterine fibroid(s) ablation with ultrasound guidance, radiofrequency	NP
XXXXB	Oversight of the care of an extracorporeal liver assist system patient requiring review of status, review of laboratories and other studies, and revision of orders and liver assist care plan (as appropriate), within a calendar month, 30 minutes or more of non-face-to-face time	NP
040XF	Nasal endoscopy, surgical, ethmoid sinus; placement of drug eluting implant	NP
040XG	Nasal endoscopy, surgical, ethmoid sinus; placement of drug eluting implant, ethmoid sinus with biopsy, polypectomy or debridement	NP
04XX1	Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator with transvenous electrodes	NP
04XX2	Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator only	NP
04XX3	Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; atrial electrode only	NP
04XX4	Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; ventricular electrode only	NP
04XX5	Removal of permanent cardiac contractility modulation system; pulse generator only	NP
04XX6	Removal of permanent cardiac contractility modulation system; transvenous electrode (atrial or ventricular)	NP

# CY 2016 OPPS/ASC PROPOSED RULE

## Addendum O: New CY 2016 Category I and III CPT Codes Effective January 1, 2016

CPT codes and descriptions only are copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.

**NOTE 1: The proposed payment rates for these codes can be found in the OPPS Addendum B, ASC Addendum AA, and ASC Addendum BB to this proposed rule, which is available via the Internet on the CMS Web site.**

**NOTE 2: Comment Indicator (CI) "NP" = New code for the next calendar year or existing code with substantial revision to its code descriptor in the next calendar year as compared to current calendar year, proposed payment indicator; comments will be accepted on the proposed payment indicator for the new code.**

**NOTE 3: Comments will NOT be accepted for new Category I CPT lab codes that are not assigned to "NP" comment indicator. Comments to these codes must be submitted at the Clinical Lab Fee Schedule (CLFS) Public Meeting, which is scheduled for July 16, 2015.**

CY 2016 OPPS/ASC Proposed Rule 5-Digit CMS Placeholder Code	Long Descriptor	Comment Indicator (CI)
04XX7	Removal and replacement of permanent cardiac contractility modulation system pulse generator only	NP
04XX8	Repositioning of previously implanted cardiac contractility modulation transvenous electrode, (atrial or ventricular lead)	NP
04XX9	Relocation of skin pocket for implanted cardiac contractility modulation pulse generator	NP
04X10	Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, implantable cardiac contractility modulation system	NP
04X11	Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording and disconnection per patient encounter; implantable cardiac contractility modulation system	NP
04X12	Destruction neurofibromata, extensive, (cutaneous, dermal extending into subcutaneous); face, head and neck, greater than 50	NP
04X13	Destruction neurofibromata, extensive, (cutaneous, dermal extending into subcutaneous); trunk and extremities, greater than 100	NP
04X14	Transurethral waterjet ablation of prostate, including control of post-operative bleeding, complete (vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, and internal urethrotomy are included when performed)	NP
04X15	Tactile breast imaging by computer-aided tactile sensors, unilateral or bilateral	NP
04X16	Secretory type II phospholipase A2 (sPLA2-IIA)	NP
04X17	Insertion or replacement of neurostimulator system for treatment of central sleep apnea; complete system (transvenous placement of right or left stimulation lead, sensing lead, implantable pulse generator)	NP
04X18	Insertion or replacement of neurostimulator system for treatment of central sleep apnea; sensing lead only	NP
04X19	Insertion or replacement of neurostimulator system for treatment of central sleep apnea; stimulation lead only	NP
04X20	Insertion or replacement of neurostimulator system for treatment of central sleep apnea; pulse generator only	NP
04X21	Removal of neurostimulator system for treatment of central sleep apnea; pulse generator only	NP
04X22	Removal of neurostimulator system for treatment of central sleep apnea; sensing lead only	NP
04X23	Removal of neurostimulator system for treatment of central sleep apnea; stimulation lead only	NP

## CY 2016 OPPS/ASC PROPOSED RULE

### Addendum O: New CY 2016 Category I and III CPT Codes Effective January 1, 2016

CPT codes and descriptions only are copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.

**NOTE 1:** The proposed payment rates for these codes can be found in the OPPS Addendum B, ASC Addendum AA, and ASC Addendum BB to this proposed rule, which is available via the Internet on the CMS Web site.

**NOTE 2:** Comment Indicator (CI) "NP" = New code for the next calendar year or existing code with substantial revision to its code descriptor in the next calendar year as compared to current calendar year, proposed payment indicator; comments will be accepted on the proposed payment indicator for the new code.

**NOTE 3:** Comments will **NOT** be accepted for new Category I CPT lab codes that are not assigned to "NP" comment indicator. Comments to these codes must be submitted at the Clinical Lab Fee Schedule (CLFS) Public Meeting, which is scheduled for July 16, 2015.

CY 2016 OPPS/ASC Proposed Rule 5-Digit CMS Placeholder Code	Long Descriptor	Comment Indicator (CI)
04X24	Removal and replacement of neurostimulator system for treatment of central sleep apnea, pulse generator only	NP
04X25	Repositioning of neurostimulator system for treatment of central sleep apnea; stimulation lead only	NP
04X26	Repositioning of neurostimulator system for treatment of central sleep apnea; sensing lead only	NP
04X27	Interrogation device evaluation implanted neurostimulator pulse generator system for central sleep apnea	NP
04X28	Programming device evaluation of implanted neurostimulator pulse generator system for central sleep apnea; single session	NP
04X29	Programming device evaluation of implanted neurostimulator pulse generator system for central sleep apnea; during sleep study	NP